Covid-19 crisis: 1 in 7 reporting side-effects from Sputnik V, says report

The Russian vaccine is still safer and at-par with global competitors, says report

Vaccine, Covid
Approximately 14 per cent have small complaints of weakness, muscle pain for 24 hours and an occasional increase in body temperature, said report
Agencies Moscow
1 min read Last Updated : Sep 18 2020 | 4:08 AM IST
New reports to come out of clinical studies have found that 1 in 7 people suffered from side-effects post being inoculated by the Russian vaccine. The Soviet nation's health minister, Mikhail Murashko, in a statement to Moscow Times said that nearly 14 per cent of patients who have been administrated the vaccine reported suffering from side-effects.

However, terming the side-effects to be mild and routine, Murashko still said that the Russian vaccine is still safer and at-par with global competitors.


“Approximately 14 per cent have small complaints of weakness, muscle pain for 24 hours and an occasional increase in body temperature,” he said.

Terming these effects to be normal, the minister also said that the symptoms were 'level off' by the next day and they would keep tracking vitals to notice adversities if any.


One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus Vaccine

Next Story